Selective serotonin re-uptake inhibitors in anorexia nervosa

Bibliography

• CARLSSON A: The discovery or the SSRIs: a milestone in neuropsychopharmacology and rational drug design. In: Selective Serotonin Reuptake Inhibitors (SSRIs). Past, Present and Future. Stanford Sc (Ed). RGLandes Company, Texas, USA (1999):1–7.
   Google Scholar
• STAHL SM: Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychophannacol Bull. (1992) 28:3–9.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH: Pharmacolkinetics of antidepressants: why and how they are relevant to treatment. I Clin. Psychiatry (1993) 54(Soppi.):14–34.
   Google Scholar
• PRESKORN SH: Targeted pharmacotherapy in depression management: comparative pharmacolkinetics of fluoxetine, paroxetine and sertraline. Int. Clin. Psychophannacol (1994) 9\(Suppl. 3):13–19. 355 Expert Op/n. lnvestig. Drugs (2004) 13(4)
   Google Scholar
• TORK I: Anatomy of the serotonergic system. Ann. NY Acad. Sci. (1990) 600:9–34.
   PubMed Web of Science ®Google Scholar
• FULLER RW, WONG DT, ROBERTSON DW et al: A selective inhibitor of serotonin uptake. Med. Res. Rev (1991) 11:17–34.
   PubMed Web of Science ®Google Scholar
• GOODWIN GM: How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. Psychiatry (1996) 57\(Suppl. 4):9–13.
   Google Scholar
• STAHL SM: Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. j Affect. Disord. (1998) 51:215–235.
   PubMed Web of Science ®Google Scholar
• DAVIS LL, YONKERS KA, TRIVEDI M et al.: The mechanism of action of SSRIs: a new hypothesis. In: Selective Serotonin Reuptake Inhibitors (SSRIs): Past, Prevent and Future. Stanford SC (Ed). RG Landes Company, Texas, USA (1999):181–182.
   Google Scholar
• BROSEN K: Drug-metabolizing enzymes and therapeutic drug monitoring in Psychiatry The]: Drug. Montt. (1996) 18:393–396.
   Google Scholar
• BAUMANN P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Gin. Pharmacokinet. (1996) 31:444–469.
   PubMed Web of Science ®Google Scholar
• STANFORD SC: Prozac: panacea or puzzle? Trends. Pharmacol Sci. (1996) 17:150–174.
   PubMed Web of Science ®Google Scholar
• DE JONGHE F, SWINKELS J: Selectiveserotonin reuptake inhibitors: Relevance of differences in their pharmacological and clinical profiles. CNS Drugs (1997) 7:452–467.
   Web of Science ®Google Scholar
• SPINA E, AVANOZO A, FACCIOLA G et al.: Effect of fluoxetine on plasma concentraion of clozapine and its major metabolites in patients with schizophrenia. mt. Clin. Psychopharmacol (1998) 13:141–145.
   PubMed Web of Science ®Google Scholar
• HEMERYCK A, BELPAIRE FM: Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curt Drug Metab. (2002) 3(1):13–37.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, SCHMIDER J et at.: Inhibition of human cytochrome P450-3A: Isoforms by fluoxetine and norfluoxetine: M vitro and in vivo studies.' Clin. Pharmacol (1996) 36:792–798.
   Google Scholar
• POLLOCK BG: Citalopram: A comprehensive review. Expert. Opin. Pharmacother. (2000) 2(4):681–698.
   Google Scholar
• BAUMANN P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. mt. Clin. Psychopharmacol (1996) 11 (Suppl. 1):5–11.
   Google Scholar
• OWENS MJ, MORGAN WN, PLOTT SJ et al.: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Pharmacol Exp. Ther. (1997) 283:1305–1322.
   PubMed Web of Science ®Google Scholar
• BAUMAN P, LARSEN F: The pharmacokinetics of citalopram. Rev Contemp. Pharmacother. (1995) 6:287–295.
   Google Scholar
• RICHELSON E: Pharmacology of antidepressants characteristics of the ideal antidepressant. Drug. Mayo. Clin. Proc. (1994) 69:1069–1081.
   PubMed Web of Science ®Google Scholar
• MURDOCH D, McTAVISHD: Sertraline.A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive compulsive disorder. Drugs (1992) 44:604–624.
   Google Scholar
• VAN HARTEN J: Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. (1995) 29\(Suppl. 1):1–9.
   Google Scholar
• KAYE CM, HADDOCK RE, LANGLEY PF et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta. Psychiatt Scand. (1989) 80\(Suppl. 350):60–75.
   Google Scholar
• VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. am Pharmacokinet. (1993) 24(3):203–220.
   PubMed Web of Science ®Google Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter Study. J. Affect. Disord. (1990) 18:289–299.
   PubMed Web of Science ®Google Scholar
• KUHS H, SCHLAKE HP, ROLF LH et al: Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta. Psychiatr. Scand. (1992) 85(5):364–369.
   PubMed Web of Science ®Google Scholar
• JEPPESEN U, GRAM L.F, VISTISEN K et al.: Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. Clin. Pharmacol (1996) 51:73–78.
   Google Scholar
• SOVEL SV: What's new in the treatment ofanorexia nervosa and bulimia? Medscape Womens Health (1996) 1:5.
   Google Scholar
• TAKIMOTO Y, INUI A, KUMANO H et al.: Orexigenidanoreidgenic signals in bulimia nervosa. Can: Ma Med. (2003) 3:349–360.
   Google Scholar
• HALMI KA. Anorexia Nervosa and Bulimia Nervosa. In: Child and Adolesc. Psychiatry: A comprehensive Text Book, 3rd edn. Melwin Lewis (Ed), Lippincott Williams and Wilikins, Philadelphia, USA (2002):692–700.
   Google Scholar
• HOEK HW: Review of the epidemiological studies of eating disorders. Int. Rev Psychiatry (1993) 5:61–74.
   Google Scholar
• GOWERS S, MCMAHON JB: Social class and prognosis in anorexia nervosa. Int. J. Eat. Disord. (1989) 8:105–110.
   Web of Science ®Google Scholar
• HOEK HW: The incidence and prevalence of anorexia nervosa and bulimia nervosa in primary care. Psycho]. Med. (1991) 21:455–460.
   PubMed Web of Science ®Google Scholar
• ECKERT E, HALMI KA, MARCHI P et al.: Comparison of bulimic and non-bulimic anorexia nervosa patients during treatment. Psycho]. Med. (1987) 17:891–898.
   PubMed Web of Science ®Google Scholar
• HALMI KA, FALK JR: Anorexia nervosa: a study of outcome discriminators in exclusive dieters and bulimics. .1 Am Acad Child Psychiatry (1982) 21:4–7.
   Google Scholar
• STROBER M, SALKIN B, BURROUGHS J: Validity of the bulimia-restrictor distinctions in anorexia nervosa: Parental personality characteristics and familial psychiatry morbidity.' Nerv. Ment Dis. (1982) 170:345–351.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED]: Diagnostic and statistical manual of mental disorders, 4th ed.test revision (DSM-IV-TR) Washington, DC: American Psychiatric Press. (2000) 583:586.
   Google Scholar
• DEMITRACK MA, LESEM MD, LIST WACK SJ et al.: CSF oxytocin in anorexia nervosa and bulimia nervosa: clinical and pathophysiologic considerations. Am. J. Psychiatry (1990) 147:882–886.
   Google Scholar
• HADIGN CM, WALSH TB, BUTTINGER C et al.: Behavioural and neuroendocrine response to meta-CPP in anorexia nervosa. Biol. Psychiatry (1995) 37:504–511
   PubMedGoogle Scholar
• FRANK GK, KAYE WH, WELTZIN TE et al.: Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. Int.' Eat. Disord. (2001) 30:57–68.
   PubMed Web of Science ®Google Scholar
• KAYE W, GENDALL K, STROBER M et al.: Serotonin neuronal functions and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol. Psychiatry (1998) 44:825–838
   PubMed Web of Science ®Google Scholar
• FAVA M, COPELAND PM, SCHWEIGER U et al.: Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am. .1. Psychiatry (1989) 146:963–971.
   Google Scholar
• SHARMA A: Anorexia nervosa and bulimianervosa: an appraisal. Drugs Today (Baw). (2001) 37:229–236.
   PubMed Web of Science ®Google Scholar
• KAYE WH, BERRETTINI W, GWIRTSMAN HE et al.: Altered cerebral spinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulemia nervosa. Arch. Gen. Psychiatry(1990) 47:548–556.
   PubMed Web of Science ®Google Scholar
• HALMI KA, ECKERT E, MARCHI P et al.: Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch. Gen. Psychiatry (1991) 48:712–718.
   PubMed Web of Science ®Google Scholar
• THEANDER S: Outcome and prognosis in anorexia nervosa and bulimia. In: Anorexia nervosa and bulimic disorders. Szmukler GI et al. (Eds), Pergamon, London, UK (1985):493–508.
   Google Scholar
• BEN-TO VIN D, WALKER K, GILCHRIST P: Outcome in patients with eating disorders: a 5 year study. Lancet (2001) 357:1254–1257.
   PubMed Web of Science ®Google Scholar
• RUSSELL GFM: Anorexia and Bulimia Nervosa. In: Child and Adolescent Psychiatry edn. Rutter M, Hersov L (Eds), Blackwell scientific publication, Oxford, UK (1985):625–637
   Google Scholar
• HALMI KA: Eating disorders (anorexia nervosa, bulimia nervosa and obesity). In: Textbook of Clinical Psychiatry Hales RE, Yudofsky SG (Eds), Am. Psychiatric Publishing, Washington DC, USA (2003) 1:1001-1021. The latest detailed description of AN.
   Google Scholar
• GARNER DM, ROCKERT W, OLMSTED MP et al.: Psycho educational principles in the treatment of bulimia and anorexia nervosa. In: Handbook of psychotherapy for anorexia nervosa and bulimia. Garner DM, Garfinkel PE (Eds), Guilford Press, New York, USA (1985):513–572.
   Google Scholar
• APA practice guidelines for the treatment ofpatients with eating disorders (revision). Am. J. Psychiatry (2000) 157:39.
   Google Scholar
• FERGUSON CP, LA VIA MC, CROSSAN PJ et al.: Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? hit. 1 Eat. Disord. (1999) 25:11–17.
   Google Scholar
• BARBARICH NC, MCCONAHA CW, HALMI KA et al.: Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int. .1. Eat. Disord. (2004) 35(1):10–5.
   Google Scholar
• MAYER LE, WALSH BT: The use of selective serotonin reuptake inhibitors in eating disorders, Clin. Psychiatry (1998) Suppl. 15:28–34.
   Google Scholar
• KIM SS: Role of fluoxetine in anorexia nervosa. Ann. Pharmacother: (2003) 37:890–892.
   PubMed Web of Science ®Google Scholar
• ••Well-summarised studies of fluoxetine inAN.
   Google Scholar
• FERGUSON JM: Treatment of an anorexia nervosa patient with fluoxetine (letter) Am. J. Psychiatry (1987) 144:1239.
   Google Scholar
• GWIRTSMAN HE, GUZE BH, YAGER J et al.: Fluoxetine treatment of anorexia nervosa: an open clinical trial." Gin. Psychiatry (1990) 51:378–382.
   Google Scholar
• KAYE WH, WELTZIN TE, HSU LK et al.: An open trial of fluoxetine in patients with anorexia nervosa.' Clin. Psychiatry (1991) 52:464–471.
   PubMed Web of Science ®Google Scholar
• ATTIA E, HAIMAN C, WALSH T et al:Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am.' Psychiatry(1998) 155:548–551.
   Google Scholar
• STROBER M, FREEMAN R, DE ANTONIO M et al: Does fluoxetine influence the post-hospital course of restrictor type anorexia nervosa? A 24 month prospective, longitudinal follow up and comparison and historical controls. Psychopharmacol Bull. (1997) 33:425–431.
   PubMed Web of Science ®Google Scholar
• KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind placebo controlled administration of fluoxetine in restricting and restricting-purging type anorexia nervosa. Biol. Psychiatry (2001) 49:644–652.
   PubMed Web of Science ®Google Scholar
• HEIDEN A, ZWAAN M, FREY R et al.: Paroxetine in a patient with obsessive-cumpulsive disorder, anorexia nervosa and schizotypal personality disorder.' Psychiatry NeuroscL (1998) 23:179–180.
   PubMed Web of Science ®Google Scholar
• SANTONASTASO P, FRIEDERICI S, FAVARO A: Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. j Child Adolsc. Psychopharmacol (2001) 11:143–150.
   PubMed Web of Science ®Google Scholar
• FRANK GK, KAYE WH, MARCUS MD: Sertraline in underweight binge eating/ purging-type eating disorders: five case reports. Int. .1. Eat. Disord. (2001) 29(4):495–498.
   Google Scholar
• FASSINO S, LEOMBRUNI P, DAGA GA et al.: Efficacy of citalopram in anorexia nervosa: a pilot study. Eur: Neuropsychopharmacol (2002) 12:453–459.
   PubMed Web of Science ®Google Scholar
• BERGH C, ERIKSSON M, LINDBERG G et al: Selective serotonin reuptake inhibitors in anorexia (letter). Lancet (1996) 348:1459–1460.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, TAREEN B, SHEEHAN W et al.: Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa. Int.' Eat. Disord. (2000) 28:1–7.
   PubMed Web of Science ®Google Scholar